SelectMDx is a post‐DRE urinary test that uses a combination of clinical data (age, DRE and PSA density) and mRNA expression of DLX1 (Distal‐Less Homeobox 1) and HOXC6 (Homeobox protein Hox‐C6) to estimate the risk of having Gleason ≥7 cancer. The gene discussed is KLK3; the disease is cancer.